Ampalex

• CAT Number: I001944
• CAS Number: 154235-83-3
• Molecular Formula: C14H15N3O
• Molecular Weight: 241.29
• Purity: ≥95%
• Synonyms: piperidin-1-yl(quinoxalin-6-yl)methanone
• Target: Neuronal Signaling
• Solubility: DMSO: ≥ 41 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2
• InChIKey: ANDGGVOPIJEHOF-UHFFFAOYSA-N
• SMILES: O=C(N1CCCCC1)C2=CC=C3N=CC=NC3=C2

Ampalex (CX-516) (Cat.No:I001944) is a positive allosteric modulator of AMPA receptors that enhances synaptic plasticity and memory consolidation. It has been investigated for the treatment of cognitive deficits associated with Alzheimer’s disease, schizophrenia, and attention-deficit/hyperactivity disorder (ADHD). Clinical trials have shown modest benefits in cognitive function but also some adverse effects, such as headache and gastrointestinal symptoms.

Reference

[1]. Broberg BV, Glenth?j BY, Dias R, et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia–sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl). 2009 Nov;206(4):631-40.
[2]. Kanju PM, Parameshwaran K, Sims C, et al. Ampakine CX516 ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. Exp Neurol. 2008 Nov;214(1):55-61.
[3]. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb;33(3):465-72.
[4]. O/’Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson/’s disease. Curr Drug Targets. 2007 May;8(5):603-20.
[5]. Johnson SA, Simmon VF. Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report. J Mol Neurosci. 2002 Aug-Oct;19(1-2):197-200.